Pulmonary rehabilitation improves exercise capacity, health-related quality of life, and cardiopulmonary function in patients with non-small cell lung cancer.
Chun-Yao Huang, Min-Shiau Hsieh, Po-Chun Hsieh...
https://pubmed.ncbi.nlm.nih.gov/38360680Actively Recruiting
Led by Ditte Krag-Hansen · Updated on 2026-04-22
280
Participants Needed
1
Research Sites
N/A
Total Duration
D
Ditte Krag-Hansen
Lead Sponsor
A
AstraZeneca
Collaborating Sponsor
Researchers are evaluating how early diagnosis and optimal treatment of Chronic Obstructive Pulmonary Disease (COPD) affect health outcomes in patients undergoing evaluation for suspected lung cancer. This study highlights the frequent coexistence of COPD and lung cancer, mainly due to shared risk factors like smoking. It aims to improve management of both diseases by focusing on integrated care approaches, potentially enhancing treatment tolerance, reducing complications, and improving overall survival. Participants are randomly assigned to either usual care or tailored COPD consultations following GOLD guidelines. The tailored consultations include pharmacological management, smoking cessation support, pulmonary rehabilitation referrals, nutritional assessment, cardiovascular evaluation, and sleep apnea assessment as needed. This is an open-label randomized controlled trial conducted at the Lung Cancer Investigation Unit at Lillebaelt Hospital Vejle. During the study, participants undergo assessments at baseline, 3 months, and 6 months, including the COPD Assessment Test (CAT) score, weight, height, BMI, 1-minute sit-to-stand test, and questionnaires on health status, anxiety, and depression. Researchers also monitor smoking cessation, exacerbations, hospitalizations, postoperative recovery, mortality, adverse events, and overall survival to evaluate the impact of early COPD management. The total study duration for participants spans 6 months with multiple follow-ups.
CONDITIONS
Enhanced COPD Management in Suspected Lung Cancer Patients
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants receive tailored COPD consultations including assessment and treatment according to GOLD guidelines, such as pharmacological management, smoking cessation support, and referrals to pulmonary rehabilitation, nutritional, cardiovascular, and sleep apnea evaluations as appropriate.
Visits at baseline, 3 months, and 6 months
Duration - 6 months
Participants undergoing usual lung cancer diagnostic evaluation without additional COPD intervention are observed during their lung cancer work-up.
Visits at baseline, 3 months, and 6 months
Total: 1 location
1
Lung Cancer Investigation Unit, Lillebaelt Hospital Vejle
Vejle, Denmark, 7100
Actively Recruiting
D
Ditte Krag-Hansen, MD, PhD student
M
Morten Hornemann Borg, MD, PhD, Chief consultant
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Chun-Yao Huang, Min-Shiau Hsieh, Po-Chun Hsieh...
https://pubmed.ncbi.nlm.nih.gov/38360680Attila Vagvolgyi, Zsolt Rozgonyi, Maria Kerti...
https://pubmed.ncbi.nlm.nih.gov/28740672Sumin Shin, Sunga Kong, Danbee Kang...
https://pubmed.ncbi.nlm.nih.gov/36042472Oliver Illini, Arschang Valipour, Dietlinde Gattinger...
https://pubmed.ncbi.nlm.nih.gov/35884540Chun-Yao Huang, Min-Shiau Hsieh, Yao-Kuang Wu...
https://pubmed.ncbi.nlm.nih.gov/34989126Dingding Deng, Dan Peng, Qing Song...
https://pubmed.ncbi.nlm.nih.gov/41313168Rong Zhou, Yan Qin, Song Hu...
https://pubmed.ncbi.nlm.nih.gov/39607005Magnus Gottlieb, Anders Mellemgaard, Kristoffer Marsaa...
https://pubmed.ncbi.nlm.nih.gov/32194927A S Zigmond, R P Snaith
https://pubmed.ncbi.nlm.nih.gov/6880820Trija Vaidya, Claire de Bisschop, Marc Beaumont...
https://pubmed.ncbi.nlm.nih.gov/27799759